Shanghai Houchao Biotechnology Co., Ltd Report issue

Government Phase 1 Phase 2
Founded: Shanghai China

Organization Overview

First Clinical Trial
2017
NCT03198923
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Shanghai Houchao Biotechnology Co., Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

neoantigen dna vaccine (1 trial)

Drugs in Phase 1 Trials (2)

allogeneic natural killer cells (1 trial)

hekt cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3